Breast Cancer Treatment Market is Expected to Reach $10,682.6 Million By 2022: Credence Research has Published New Research Report Title “Global Breast Cancer Treatment Market By Drug Type (HER2 Inhibitors, Mitotic Inhibitors, Anti-metabolites, Aromatase Inhibitors, Hormone Receptor Antagonists) – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022”

The latest market report published by Credence Research, Inc. “Global Breast Cancer Treatment Market – Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 – 2022,” the breast cancer treatment market was valued at USD 10,682.6 Mn in 2015, and is expected to reach USD 17,345.8 Mn by 2022, expanding at a CAGR of 7.6% from 2016 to 2022.

Market Insights:

Breast cancer is typically detected either during a screening examination, before symptoms have developed, or after a woman notices a lump. According to market experts, breast cancer is the second-largest cause of cancer deaths globally. The rising prevalence of breast cancer across the developed nations has boosted the involvement of non-governmental associations that are spreading awareness related to breast cancer diagnostics and treatment in public. Therapeutic treatment preferred to treat breast cancer involves synthetic to biological drugs. The awareness created around the world in last decade has assisted the market growth along with market introduction of premium priced therapies. Moreover, drugs for breast cancer have seen accelerated approvals, thereby providing impetus for breast cancer research and shifting the equilibrium toward research of new effective pathways for intervention of breast cancer. On the other hand, the geographical analysis of breast cancer treatment market projected North America and Europe as the dominant regions followed by Asia-Pacific.  The key factors driving the breast cancer market in the world include developed research and development facilities, upcoming drug launches, and mounting incidences and awareness of the breast cancer in developing countries. Thus, rising incidences of breast cancer and novel product approvals will lead to significant market growth during the forecast period, despite generic sales erosion resulting from patent expirations.

Browse the full report Breast Cancer Treatment Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at

Pipeline Analysis:

The phase III drugs included in the pipeline analysis are Abemaciclib (Eli Lily & Company), Buparlisib (Novartis), NeuVax (Galena Biopharma), Niraparib (Tesaro), Lynparza (AstraZeneca), Veliparib (AbbVie), Neratinib (Puma Biotechnology), Ribociclib (Novartis) and others. According to market experts, these upcoming drugs assure to provide enhanced efficacy, shorter onset of action and fewer side effects as compared to the currently available breast cancer treatment. Thus, future commercialization of these molecules during the forecast period 2016 – 2022 is anticipated to have a reflective impact on the growth of the overall breast cancer treatment market.

Key Market Movements:

  • North America presently dominates the overall market and is also projected to experience the fastest growth throughout the forecast period
  • The recent market entry of novel drugs including Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate; and Halaven, a novel chemotherapeutic agent have boosted the overall growth of breast cancer treatment market
  • The companies have been able to develop efficient and commercially successful products by studying pathophysiology of breast cancer in detail, e.g. Herceptin, which is build on the existing scientific groundwork.

Latest Report:

Autoimmune Diseases Treatment Market – Growth, Share, Opportunities & Competitive Analysis, 2016 – 2022

About Us:

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.

Who we are

Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.

Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa. 

Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.

What we do

We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.

No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.


Name: Chris Smith

Designation: Global Sales Manager


Ph: 1-800-361-8290

Web:  Credence Research


Media Contact
Company Name: Credence Research
Contact Person: Chris Smith, Global Sales Manager
Email: Send Email
Phone: 1-800-361-8290
Address:105 N 1st ST #429
State: California
Country: United States